DTC Survey Examines Quantitative Claims

Federal Register notice: FDA has sent to OMB an information collection proposal entitled “A Survey on Quantitative Claims in Direct-to-Consumer (DTC) Prescription Drug Advertising.” DTC prescription drug advertising may make quantitative claims about a drug’s efficacy or risks, and the agency has research and guidance available that provides general guidelines on how to present such information, but it says it is not fully understood how consumers will interpret specific quantitative claims. FDA says the survey is intended to answer how consumers interpret different claims describing medians (e.g., “People treated with Drug X lived for a median of eight months.” It also contains questions about respondents’ perceptions and understanding of several quantitative claims drawn from DTC ads in the marketplace. “We will also measure other potentially important variables, such as demographics and numeracy,” the agency says. To view the notice, click here.